As described above, and summarized in Figure 2 and Table 2, Table 3 and Table 4, it appears that while inhibition of Annexin A1 may offer therapeutic advantage in renal cancer and nephrolithiasis, for most of the other conditions potentiation/facilitation of Annexin A1 signaling may be advantageous. The gene discussed is ANXA1; the disease is nephrolithiasis.